Identification and characterization of tumorigenic liver cancer stem/progenitor cells - PubMed (original) (raw)
. 2007 Jun;132(7):2542-56.
doi: 10.1053/j.gastro.2007.04.025. Epub 2007 Apr 15.
Affiliations
- PMID: 17570225
- DOI: 10.1053/j.gastro.2007.04.025
Identification and characterization of tumorigenic liver cancer stem/progenitor cells
Stephanie Ma et al. Gastroenterology. 2007 Jun.
Abstract
Background & aims: Recent efforts in stem cell biology suggest that tumors are organized in a hierarchy of heterogeneous cell populations and that the capability to maintain tumor formation/growth specifically resides in a small population of cells called cancer stem cells (CSCs). The aim of this study is to identify, isolate, and characterize the CSC population that drives and maintains hepatocellular carcinoma (HCC) growth and metastasis.
Methods: Normal stem cells involved in liver regeneration were identified using a severe partial hepatectomy model. Purified HCC cells, with or without expression of the identified normal stem cell phenotype, were evaluated, based on their tumorigenic potential and exhibition of defined stem/progenitor cell-like properties, to determine whether liver CSCs can be or partly be identified by this surface marker.
Results: We report the identification and isolation of a population of CSCs expressing a CD133 surface phenotype from human liver cell lines. CD133(+) cells possess a greater colony-forming efficiency, higher proliferative output, and greater ability to form tumor in vivo. These cells are endowed with characteristics similar to those of progenitor cells including the expression of "stemness" genes, the ability to self-renew, and the ability to differentiate into nonhepatocyte-like lineages. Furthermore, CD133 is found to represent only a minority of the tumor cell population in human HCC specimens.
Conclusions: We report the identification of a CSC population in HCC characterized by their CD133 phenotype. The identification of tumorigenic liver CSCs could provide new insight into the HCC tumorigenic process and possibly bear great therapeutic implications.
Similar articles
- Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.
Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ, Guan XY. Ma S, et al. Mol Cancer Res. 2008 Jul;6(7):1146-53. doi: 10.1158/1541-7786.MCR-08-0035. Mol Cancer Res. 2008. PMID: 18644979 - miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, Ng I, Man K, Wong N, To KF, Zheng BJ, Lai PB, Lo CM, Chan KW, Guan XY. Ma S, et al. Cell Stem Cell. 2010 Dec 3;7(6):694-707. doi: 10.1016/j.stem.2010.11.010. Cell Stem Cell. 2010. PMID: 21112564 - CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.
Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, Ng IO, Man K, To KF, Lai PB, Lo CM, Guan XY, Chan KW. Tang KH, et al. Hepatology. 2012 Mar;55(3):807-20. doi: 10.1002/hep.24739. Epub 2012 Jan 13. Hepatology. 2012. PMID: 21994122 - Biology and clinical implications of CD133(+) liver cancer stem cells.
Ma S. Ma S. Exp Cell Res. 2013 Jan 15;319(2):126-32. doi: 10.1016/j.yexcr.2012.09.007. Epub 2012 Sep 19. Exp Cell Res. 2013. PMID: 22999864 Review. - [Progress and prospects in cancer stem cell research for hepatocellular carcinoma].
Xu W, Cao L, Yin ZF. Xu W, et al. Ai Zheng. 2009 Sep;28(9):1004-8. doi: 10.5732/cjc.008.10835. Ai Zheng. 2009. PMID: 19728923 Review. Chinese.
Cited by
- Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis.
Uehara T, Ainslie GR, Kutanzi K, Pogribny IP, Muskhelishvili L, Izawa T, Yamate J, Kosyk O, Shymonyak S, Bradford BU, Boorman GA, Bataller R, Rusyn I. Uehara T, et al. Toxicol Sci. 2013 Mar;132(1):53-63. doi: 10.1093/toxsci/kfs342. Epub 2013 Jan 3. Toxicol Sci. 2013. PMID: 23288052 Free PMC article. - ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma.
Tong M, Fung TM, Luk ST, Ng KY, Lee TK, Lin CH, Yam JW, Chan KW, Ng F, Zheng BJ, Yuan YF, Xie D, Lo CM, Man K, Guan XY, Ma S. Tong M, et al. Stem Cell Reports. 2015 Jul 14;5(1):45-59. doi: 10.1016/j.stemcr.2015.05.013. Epub 2015 Jun 18. Stem Cell Reports. 2015. PMID: 26095609 Free PMC article. - Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma.
Romano M, De Francesco F, Pirozzi G, Gringeri E, Boetto R, Di Domenico M, Zavan B, Ferraro GA, Cillo U. Romano M, et al. Oncoscience. 2015 May 15;2(5):443-456. doi: 10.18632/oncoscience.163. eCollection 2015. Oncoscience. 2015. PMID: 26097877 Free PMC article. Review. - Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.
Duong HQ, Hwang JS, Kim HJ, Kang HJ, Seong YS, Bae I. Duong HQ, et al. Int J Oncol. 2012 Sep;41(3):855-61. doi: 10.3892/ijo.2012.1516. Epub 2012 Jun 12. Int J Oncol. 2012. PMID: 22710732 Free PMC article. - Oncogenic signaling pathways and origins of tumor-initiating stem-like cells of hepatocellular carcinomas induced by hepatitis C virus, alcohol and/or obesity.
Chen CL, Tsukamoto H, Machida K. Chen CL, et al. Hepatol Int. 2014 Jul;8(3):330-8. doi: 10.1007/s12072-014-9545-5. Epub 2014 Jun 20. Hepatol Int. 2014. PMID: 26202636 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials